Feedback / Questions
patritumab deruxtecan (U3-1402) - Daiichi Sankyo, Merck (MSD)
Patritumab deruxtecan: Primary PFS data from P3 HERTHENA-Lung02 trial (NCT05338970) 2L EGFR mutated NSCLC at ASCO (May 30-Jun 03, 2025)
(Daiichi Sankyo)
-
May 7, 2025 -
FY2024 Results
P3 data
•
Lung Cancer • Non Small Cell Lung Cancer • Oncology
https://www.daiichisankyo.com/files/investors/library/quarterly_result/2024/4Q/FY2024Q4_Financial_Results_Presentation_E.pdf
May 7, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious